Applied Dna Sciences (BNBX) Stock Price, News & Analysis

Company Overview

Applied DNA Sciences is a U.S.-based biotechnology company that develops and commercializes molecular-level solutions for product authentication, supply chain security and forensic identification. The company’s technologies apply unique DNA markers and laboratory testing methods to tag, track and verify the authenticity of goods and materials, with the goal of combating counterfeiting, diversion and fraud across complex supply chains.

Central to Applied DNA’s offering is a suite of proprietary DNA-based markers and associated assays that can be incorporated into inks, fibers, coatings and other substrates to create tamper-evident, forensic-grade identifiers. The company supports those markers with laboratory services—using PCR and sequencing techniques—to analyze samples, produce digital chain-of-custody reports and provide verification for customers. Its business model includes product sales, licensing and contract testing or integration work tailored to customer requirements.

Applied DNA’s solutions are used by organizations that need robust provenance and anti-counterfeiting measures, including manufacturers, distributors and entities in regulated industries. The company provides services to customers in the United States and internationally, seeking to address global supply-chain vulnerabilities by combining intellectual property, laboratory capability and field-deployable tagging technologies. Applied DNA Sciences is publicly traded on the NASDAQ.

Key Stats

• Today's Range: $0.14 to $0.16
• 50-Day Range: $0.08 to $0.54
• 52-Week Range: $0.07 to $7.15
• Volume: 88,013 shs
• Average Volume: 484,908 shs
• Market Capitalization: $1.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Applied Dna Sciences Stock Analysis - MarketRank™

Applied Dna Sciences scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Applied Dna Sciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Applied Dna Sciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Applied Dna Sciences is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Applied Dna Sciences is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Applied Dna Sciences has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BNBX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Applied Dna Sciences does not currently pay a dividend.

Dividend Growth

Applied Dna Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 0.7 / 5
• News Sentiment: N/A

News Sentiment

Applied Dna Sciences has a news sentiment score of -0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Applied Dna Sciences this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Applied Dna Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.14% of the stock of Applied Dna Sciences is held by insiders.

Percentage Held by Institutions

22.22% of the stock of Applied Dna Sciences is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 8/14/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BNBX
• CIK: 744452
• Web: adnas.com
• Phone: (631) 240-8800
• Fax: 631-240-8900
• Employees: 70
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($36.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.16 million
• Net Margins: -1,647.25%
• Pretax Margin: -1,671.00%
• Return on Equity: -349.95%
• Return on Assets: -283.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.82
• Quick Ratio: 1.74

Sales & Book Value

• Annual Sales: $2.09 million
• Price / Sales: 0.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.50 per share
• Price / Book: 0.10

Miscellaneous

• Outstanding Shares: 7,197,000
• Free Float: 6,755,000
• Market Cap: $1.04 million
• Optionable: N/A
• Beta: 0.60